Home
Welcome to Zietchick Research Institute, where we develop revolutionary treatments that can prevent retinopathy among women and children.
One of our areas of focus is developing big treatments for little eyes by creating eye treatments for premature infants. Premature babies may be deprived of hormones that are critical to their eye development. We are creating the world’s first eyedrops for premature babies that are designed to replace the lost placental nutrients so that their eyes can develop naturally even outside of the womb. This will help reduce instances of retinopathy of prematurity.
We are also focusing on developing new treatments for proliferative retinopathy. Through our extensive research efforts, we have determined that females with the eye condition have increased hormones in their eyes. We are developing eyedrops that are designed to counteract these excess hormones.
Now, the majority of eye drops on the market are not designed to treat diseases that affect the back of the eye. We plan to utilize nanoparticles to help deliver our drug to the back of the eye, where it can help treat the eye disease.
We hope that through these efforts, we would be one step closer to reducing retinopathy once and for all.
One of our areas of focus is developing big treatments for little eyes by creating eye treatments for premature infants. Premature babies may be deprived of hormones that are critical to their eye development. We are creating the world’s first eyedrops for premature babies that are designed to replace the lost placental nutrients so that their eyes can develop naturally even outside of the womb. This will help reduce instances of retinopathy of prematurity.
We are also focusing on developing new treatments for proliferative retinopathy. Through our extensive research efforts, we have determined that females with the eye condition have increased hormones in their eyes. We are developing eyedrops that are designed to counteract these excess hormones.
Now, the majority of eye drops on the market are not designed to treat diseases that affect the back of the eye. We plan to utilize nanoparticles to help deliver our drug to the back of the eye, where it can help treat the eye disease.
We hope that through these efforts, we would be one step closer to reducing retinopathy once and for all.
Comments
Post a Comment